Open-label, Dose-escalation Phase 1 Clinical Study of SENL101 Autologous T Cell Injection in the Treatment of Adult Patients With Relapsed or Refractory T-LBL/ALL

Study Summary

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

Interventions

Study Locations

Facility	City	State	Country
Shanghai Ruijin Hospital	Shanghai		China

Official Trial Information

View on ClinicalTrials.gov